Cargando...
Selective use of vandetanib in the treatment of thyroid cancer
Vandetanib is a once-daily orally available tyrosine kinase inhibitor that works by blocking RET (REarranged during Transfection), vascular endothelial growth factor receptor (VEGFR-2, VEGFR-3), and epidermal growth factor receptor and to a lesser extent VEGFR-1, which are important targets in thyro...
Gardado en:
| Publicado en: | Drug Des Devel Ther |
|---|---|
| Main Authors: | , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Dove Medical Press
2015
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4498730/ https://ncbi.nlm.nih.gov/pubmed/26170630 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S72495 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|